featured
Mavacamten Improves Health Status of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Mavacamten for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM): Health Status Analysis of a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial
Lancet 2021 May 14;[EPub Ahead of Print], JA Spertus, JT Fine, P Elliott, CY Ho, I Olivotto, S Saberi, W Li, C Dolan, M Reaney, AJ Sehnert, D JacobyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.